{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T22:18:01Z","timestamp":1782944281058,"version":"3.54.5"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,7,13]],"date-time":"2015-07-13T00:00:00Z","timestamp":1436745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,7,13]],"date-time":"2015-07-13T00:00:00Z","timestamp":1436745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2016,3,24]]},"DOI":"10.1038\/onc.2015.217","type":"journal-article","created":{"date-parts":[[2015,7,13]],"date-time":"2015-07-13T10:03:32Z","timestamp":1436781812000},"page":"1529-1540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Dysregulated protease activated receptor 1 (PAR1) promotes metastatic phenotype in breast cancer through HMGA2"],"prefix":"10.1038","volume":"35","author":[{"given":"E","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Cisowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"O'Callaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Kuliopulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Covic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,13]]},"reference":[{"key":"BFonc2015217_CR1","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/0092-8674(91)90261-V","volume":"64","author":"T-KH Vu","year":"1991","unstructured":"Vu T-KH, Hung DT, Wheaton VI, Coughlin SR . Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor action. Cell 1991; 64: 1057\u20131068.","journal-title":"Cell"},{"key":"BFonc2015217_CR2","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nm0898-909","volume":"4","author":"S Even-Ram","year":"1998","unstructured":"Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998; 4: 909\u2013914.","journal-title":"Nat Med"},{"key":"BFonc2015217_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/sj.bjc.6690063","volume":"79","author":"KP Henrikson","year":"1999","unstructured":"Henrikson KP, Salazar SL, Fenton JW, Pentecost BT . Role of thrombin receptor in breast cancer invasiveness. Br J Cancer 1999; 79: 401\u2013406.","journal-title":"Br J Cancer"},{"key":"BFonc2015217_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ajpath.2011.03.025","volume":"179","author":"J Cisowski","year":"2011","unstructured":"Cisowski J, O'Callaghan K, Kuliopulos A, Yang J, Nguyen N, Deng Q et al. Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer. Am J Pathol 2011; 179: 513\u2013523.","journal-title":"Am J Pathol"},{"key":"BFonc2015217_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1023\/A:1014598904644","volume":"19","author":"C Rudroff","year":"2002","unstructured":"Rudroff C, Seibold S, Kaufmann R, Zetina CC, Reise K, Schafer U et al. Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro. Clin Exp Metastasis 2002; 19: 181\u2013189.","journal-title":"Clin Exp Metastasis"},{"key":"BFonc2015217_CR6","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1182\/blood.V92.10.3694","volume":"92","author":"ML Nierodzik","year":"1998","unstructured":"Nierodzik ML, Chen K, Takeshita K, Li JJ, Huang YQ, Feng XS et al. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 1998; 92: 3694\u20133700.","journal-title":"Blood"},{"key":"BFonc2015217_CR7","doi-asserted-by":"publisher","first-page":"10952","DOI":"10.1074\/jbc.M007027200","volume":"276","author":"SC Even-Ram","year":"2001","unstructured":"Even-Ram SC, Maoz M, Pokroy E, Reich R, Katz B-Z, Gutwein P et al. Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin. J Biol Chem 2001; 276: 10952\u201310962.","journal-title":"J Biol Chem"},{"key":"BFonc2015217_CR8","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1038\/sj.onc.1206453","volume":"22","author":"C Tellez","year":"2003","unstructured":"Tellez C, Bar-Eli M . Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene 2003; 22: 3130\u20133137.","journal-title":"Oncogene"},{"key":"BFonc2015217_CR9","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1128\/MCB.15.2.704","volume":"15","author":"I Whitehead","year":"1995","unstructured":"Whitehead I, Kirk H, Kay R . Expression cloning of oncogenes by retroviral transfer of cDNA libraries. Mol Cell Biol 1995; 15: 704\u2013710.","journal-title":"Mol Cell Biol"},{"key":"BFonc2015217_CR10","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1038\/sj.onc.1204281","volume":"20","author":"CB Martin","year":"2001","unstructured":"Martin CB, Mahon GM, Klinger MB, Kay RJ, Symons M, Der CJ et al. The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways. Oncogene 2001; 20: 1953\u20131963.","journal-title":"Oncogene"},{"key":"BFonc2015217_CR11","first-page":"7167","volume":"63","author":"JE Korkola","year":"2003","unstructured":"Korkola JE, DeVries S, Fridlyand J, Hwang ES, Estep ALH, Chen Y-Y et al. Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 2003; 63: 7167\u20137175.","journal-title":"Cancer Res"},{"key":"BFonc2015217_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.cell.2004.12.018","volume":"120","author":"A Boire","year":"2005","unstructured":"Boire A, Covic L, Agarwal A, Jacques S, Sharifi S, Kuliopulos A . PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005; 120: 303\u2013313.","journal-title":"Cell"},{"key":"BFonc2015217_CR13","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1158\/1535-7163.MCT-08-0177","volume":"7","author":"A Agarwal","year":"2008","unstructured":"Agarwal A, Covic L, Sevigny LM, Kaneider NC, Lazarides K, Azabdaftari G et al. Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol Cancer Ther 2008; 7: 2746\u20132757.","journal-title":"Mol Cancer Ther"},{"key":"BFonc2015217_CR14","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1158\/0008-5472.CAN-05-2082","volume":"66","author":"N Nguyen","year":"2006","unstructured":"Nguyen N, Kuliopulos A, Graham RA, Covic L . Tumor-derived Cyr61(CCN1) promotes stromal matrix metalloprotease-1 production and protease-activated receptor 1-dependent migration of breast cancer cells. Cancer Res 2006; 66: 2658\u20132665.","journal-title":"Cancer Res"},{"key":"BFonc2015217_CR15","doi-asserted-by":"publisher","first-page":"6223","DOI":"10.1158\/0008-5472.CAN-09-0187","volume":"69","author":"E Yang","year":"2009","unstructured":"Yang E, Boire A, Agarwal A, Nguyen N, O'Callaghan K, Tu P et al. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res 2009; 69: 6223\u20136231.","journal-title":"Cancer Res"},{"key":"BFonc2015217_CR16","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747\u2013752.","journal-title":"Nature"},{"key":"BFonc2015217_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrm1835","volume":"7","author":"JP Thiery","year":"2006","unstructured":"Thiery JP, Sleeman JP . Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7: 131\u2013142.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFonc2015217_CR18","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1182\/blood-2007-02-075440","volume":"110","author":"SH Slofstra","year":"2007","unstructured":"Slofstra SH, Bijlsma MF, Groot AP, Reitsma PH, Lindhout T, ten Cate H et al. Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation. Blood 2007; 110: 3176\u20133182.","journal-title":"Blood"},{"key":"BFonc2015217_CR19","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00018-011-0735-1","volume":"68","author":"A Satelli","year":"2011","unstructured":"Satelli A, Li S . Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 2011; 68: 3033\u20133046.","journal-title":"Cell Mol Life Sci"},{"key":"BFonc2015217_CR20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/35036374","volume":"2","author":"G Bergers","year":"2000","unstructured":"Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737\u2013744.","journal-title":"Nat Cell Biol"},{"key":"BFonc2015217_CR21","doi-asserted-by":"publisher","first-page":"6979","DOI":"10.1038\/sj.onc.1210508","volume":"26","author":"K Aigner","year":"2007","unstructured":"Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M et al. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 2007; 26: 6979\u20136988.","journal-title":"Oncogene"},{"key":"BFonc2015217_CR22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1242\/jcs.00224","volume":"116","author":"V Bolos","year":"2003","unstructured":"Bolos V, Peinado H, Perez-Moreno MA, Fraga MF, Esteller M, Cano A . The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci 2003; 116: 499\u2013511.","journal-title":"J Cell Sci"},{"key":"BFonc2015217_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/35000025","volume":"2","author":"A Cano","year":"2000","unstructured":"Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2: 76\u201383.","journal-title":"Nat Cell Biol"},{"key":"BFonc2015217_CR24","first-page":"37","volume":"151","author":"G Tallini","year":"1997","unstructured":"Tallini G, Dal Cin P, Rhoden KJ, Chiapetta G, Manfioletti G, Giancotti V et al. Expression of HMGI-C and HMGI(Y) in ordinary lipoma and atypical lipomatous tumors: immunohistochemical reactivity correlates with karyotypic alterations. Am J Pathol 1997; 151: 37\u201343.","journal-title":"Am J Pathol"},{"key":"BFonc2015217_CR25","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/gcc.20483","volume":"46","author":"F Medeiros","year":"2007","unstructured":"Medeiros F, Erickson-Johnson MR, Keeney GL, Clayton AC, Nascimento AG, Wang X et al. Frequency and characterization of HMGA2 and HMGA1 rearrangements in mesenchymal tumors of the lower genital tract. Genes Chromosomes Cancer 2007; 46: 981\u2013990.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFonc2015217_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000297717","volume":"5","author":"S Peluso","year":"2010","unstructured":"Peluso S, Chiappetta G . High-mobility group A (HMGA) proteins and breast cancer. Breast Care (Basel) 2010; 5: 81\u201385.","journal-title":"Breast Care (Basel)"},{"key":"BFonc2015217_CR27","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.18632\/oncotarget.1136","volume":"4","author":"S Pegoraro","year":"2013","unstructured":"Pegoraro S, Ros G, Piazza S, Sommaggio R, Ciani Y, Rosato A et al. HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. Oncotarget 2013; 4: 1293\u20131308.","journal-title":"Oncotarget"},{"key":"BFonc2015217_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bbagrm.2009.09.001","volume":"1799","author":"R Reeves","year":"2010","unstructured":"Reeves R . Nuclear functions of the HMG proteins. Biochim Biophys Acta 2010; 1799: 3\u201314.","journal-title":"Biochim Biophys Acta"},{"key":"BFonc2015217_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bbagrm.2009.08.009","volume":"1799","author":"R Sgarra","year":"2010","unstructured":"Sgarra R, Zammitti S, Lo Sardo A, Maurizio E, Arnoldo L, Pegoraro S et al. HMGA molecular network: From transcriptional regulation to chromatin remodeling. Biochim Biophys Acta 2010; 1799: 37\u201347.","journal-title":"Biochim Biophys Acta"},{"key":"BFonc2015217_CR30","first-page":"162","volume":"1796","author":"JQ Chen","year":"2009","unstructured":"Chen JQ, Russo J . ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta 2009; 1796: 162\u2013175.","journal-title":"Biochim Biophys Acta"},{"key":"BFonc2015217_CR31","doi-asserted-by":"publisher","first-page":"4572","DOI":"10.1021\/bi9824792","volume":"38","author":"A Kuliopulos","year":"1999","unstructured":"Kuliopulos A, Covic L, Seeley SK, Sheridan PJ, Helin J, Costello CE . Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy. Biochemistry 1999; 38: 4572\u20134585.","journal-title":"Biochemistry"},{"key":"BFonc2015217_CR32","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1128\/MCB.3.6.1146","volume":"3","author":"WJ Nelson","year":"1983","unstructured":"Nelson WJ, Traub P . Proteolysis of vimentin and desmin by the Ca2+-activated proteinase specific for these intermediate filament proteins. Mol Cell Biol 1983; 3: 1146\u20131156.","journal-title":"Mol Cell Biol"},{"key":"BFonc2015217_CR33","doi-asserted-by":"publisher","first-page":"e10105","DOI":"10.1371\/journal.pone.0010105","volume":"5","author":"G Lahat","year":"2010","unstructured":"Lahat G, Zhu QS, Huang KL, Wang S, Bolshakov S, Liu J et al. Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One 2010; 5: e10105.","journal-title":"PLoS One"},{"key":"BFonc2015217_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.yexcr.2004.08.015","volume":"302","author":"JM Sun","year":"2005","unstructured":"Sun JM, Spencer VA, Li L, Yu Chen H, Yu J, Davie JR . Estrogen regulation of trefoil factor 1 expression by estrogen receptor alpha and Sp proteins. Exp Cell Res 2005; 302: 96\u2013107.","journal-title":"Exp Cell Res"},{"key":"BFonc2015217_CR35","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","volume":"133","author":"SA Mani","year":"2008","unstructured":"Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704\u2013715.","journal-title":"Cell"},{"key":"BFonc2015217_CR36","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1158\/1541-7786.MCR-06-0331","volume":"5","author":"I Cleynen","year":"2007","unstructured":"Cleynen I, Brants JR, Peeters K, Deckers R, Debiec-Rychter M, Sciot R et al. HMGA2 regulates transcription of the Imp2 gene via an intronic regulatory element in cooperation with nuclear factor-kappaB. Mol Cancer Res 2007; 5: 363\u2013372.","journal-title":"Mol Cancer Res"},{"key":"BFonc2015217_CR37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/00125480-199909000-00001","volume":"6","author":"G Tallini","year":"1999","unstructured":"Tallini G, Dal Cin P . HMGI(Y) and HMGI-C dysregulation: a common occurrence in human tumors. Adv Anat Pathol 1999; 6: 237\u2013246.","journal-title":"Adv Anat Pathol"},{"key":"BFonc2015217_CR38","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1096\/fj.04-2386com","volume":"19","author":"Z Salah","year":"2005","unstructured":"Salah Z, Maoz M, Cohen I, Pizov G, Pode D, Runge MS et al. Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression. FASEB J 2005; 19: 62\u201372.","journal-title":"FASEB J"},{"key":"BFonc2015217_CR39","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1096\/fj.11-194704","volume":"26","author":"Z Salah","year":"2012","unstructured":"Salah Z, Uziely B, Jaber M, Maoz M, Cohen I, Hamburger T et al. Regulation of human protease-activated receptor 1 (hPar1) gene expression in breast cancer by estrogen. FASEB J 2012; 26: 2031\u20132042.","journal-title":"FASEB J"},{"key":"BFonc2015217_CR40","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1093\/nar\/gkg403","volume":"31","author":"M Ferguson","year":"2003","unstructured":"Ferguson M, Henry PA, Currie RA . Histone deacetylase inhibition is associated with transcriptional repression of the Hmga2 gene. Nucleic Acids Res 2003; 31: 3123\u20133133.","journal-title":"Nucleic Acids Res"},{"key":"BFonc2015217_CR41","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/nature12785","volume":"505","author":"MS Kumar","year":"2014","unstructured":"Kumar MS, Armenteros-Monterroso E, East P, Chakravorty P, Matthews N, Winslow MM et al. HMGA2 functions as a competing endogenous RNA to promote lung cancer progression. Nature 2014; 505: 212\u2013217.","journal-title":"Nature"},{"key":"BFonc2015217_CR42","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/jid.2014.480","volume":"135","author":"YS Sheen","year":"2014","unstructured":"Sheen YS, Liao YH, Lin MH, Chu CY, Ho BY, Hsieh MC et al. IMP-3 promotes migration and invasion of melanoma cells by modulating the expression of HMGA2 and predicts poor prognosis in melanoma. J Invest Dermatol 2014; 135: 1065\u20131073.","journal-title":"J Invest Dermatol"},{"key":"BFonc2015217_CR43","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.canlet.2014.09.007","volume":"355","author":"Y Li","year":"2014","unstructured":"Li Y, Zhao Z, Xu C, Zhou Z, Zhu Z, You T . HMGA2 induces transcription factor Slug expression to promote epithelial-to-mesenchymal transition and contributes to colon cancer progression. Cancer Lett 2014; 355: 130\u2013140.","journal-title":"Cancer Lett"},{"key":"BFonc2015217_CR44","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S1995-7645(14)60040-7","volume":"7","author":"YN Xi","year":"2014","unstructured":"Xi YN, Xin XY, Ye HM . Effects of HMGA2 on malignant degree, invasion, metastasis, proliferation and cellular morphology of ovarian cancer cells. Asian Pac J Trop Med 2014; 7: 289\u2013292.","journal-title":"Asian Pac J Trop Med"},{"key":"BFonc2015217_CR45","doi-asserted-by":"publisher","first-page":"33437","DOI":"10.1074\/jbc.M802016200","volume":"283","author":"S Thuault","year":"2008","unstructured":"Thuault S, Tan EJ, Peinado H, Cano A, Heldin CH, Moustakas A . HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J Biol Chem 2008; 283: 33437\u201333446.","journal-title":"J Biol Chem"},{"key":"BFonc2015217_CR46","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(09)60230-0","volume":"373","author":"RC Becker","year":"2009","unstructured":"Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009; 373: 919\u2013928.","journal-title":"Lancet"},{"key":"BFonc2015217_CR47","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","volume":"366","author":"DA Morrow","year":"2012","unstructured":"Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404\u20131413.","journal-title":"N Engl J Med"},{"key":"BFonc2015217_CR48","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1109719","volume":"366","author":"P Tricoci","year":"2012","unstructured":"Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366: 20\u201333.","journal-title":"N Engl J Med"},{"key":"BFonc2015217_CR49","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1161\/CIRCULATIONAHA.112.091918","volume":"126","author":"P Zhang","year":"2012","unstructured":"Zhang P, Gruber A, Kasuda S, Kimmelstiel C, O'Callaghan K, Cox DH et al. Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation 2012; 126: 83\u201391.","journal-title":"Circulation"},{"key":"BFonc2015217_CR50","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/nm760","volume":"8","author":"L Covic","year":"2002","unstructured":"Covic L, Misra M, Badar J, Singh C, Kuliopulos A . Pepducin-based intervention of thrombin receptor signaling and systemic platelet activation. Nat Med 2002; 8: 1161\u20131165.","journal-title":"Nat Med"},{"key":"BFonc2015217_CR51","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1158\/0008-5472.CAN-07-5793","volume":"68","author":"M Hatziapostolou","year":"2008","unstructured":"Hatziapostolou M, Polytarchou C, Panutsopulos D, Covic L, Tsichlis PN . Proteinase-activated receptor-1-triggered activation of tumor progression locus-2 promotes actin cytoskeleton reorganization and cell migration. Cancer Res 2008; 68: 1851\u20131861.","journal-title":"Cancer Res"},{"key":"BFonc2015217_CR52","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1021\/bi9927078","volume":"39","author":"L Covic","year":"2000","unstructured":"Covic L, Gresser AL, Kuliopulos A . Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry 2000; 39: 5458\u20135467.","journal-title":"Biochemistry"},{"key":"BFonc2015217_CR53","first-page":"5933","volume":"61","author":"L Kamath","year":"2001","unstructured":"Kamath L, Meydani A, Foss F, Kuliopulos A . Signaling from protease-activated receptor-1 inhibits migration and invasion of breast cancer cells. Cancer Res 2001; 61: 5933\u20135940.","journal-title":"Cancer Res"},{"key":"BFonc2015217_CR54","doi-asserted-by":"publisher","first-page":"21737","DOI":"10.1073\/pnas.1007863107","volume":"107","author":"CM Fillmore","year":"2010","unstructured":"Fillmore CM, Gupta PB, Rudnick JA, Caballero S, Keller PJ, Lander ES et al. Estrogen expands breast cancer stem-like cells through paracrine FGF\/Tbx3 signaling. Proc Natl Acad Sci USA 2010; 107: 21737\u201321742.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2015217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2015217","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2015217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T20:12:37Z","timestamp":1647893557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2015217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,13]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,3,24]]}},"alternative-id":["BFonc2015217"],"URL":"https:\/\/doi.org\/10.1038\/onc.2015.217","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,13]]},"assertion":[{"value":"26 September 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}